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Treatment effects of reverse total shoulder
arthroplasty – a simple method to measure
outcomes at 6, 12, 24 and 60months for
each patient
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Abstract
Background: Although shoulder arthroplasty is less common than knee or hip arthroplasty, the number of
procedures being performed is increasing rapidly. The treatment effect is a simple method to measure outcome of
joint replacement. The method was applied to measure results of total hip/knee arthroplasty but not yet for
shoulder arthroplasty.
Methods: Included were patients with unilateral cuff arthropathy (Hamada grades > = 2) treated with reversed total
shoulder arthroplasty (RSA) in this prospective multicenter study. The patients were assessed with the ASES
questionnaire. The treatment effects (TE) was calculated for each patient. TE = score reduction/baseline score. A
positive TE means amelioration, TE = 0 unchanged, and a negative TE means worse. The primary aim was to
calculate the TE’s for RSA at 6, 12, 24, and 60 months postoperatively. The secondary aim was to analyze the
influence of confounders (preoperative Hamada grade, age, gender, dominance, side of the affected shoulder,
general co-morbidities measured using ASA grade).
Results: Two hundred three patients were included for this analysis of whom 183 patients had a complete 2 year
follow up. Two years postoperatively the mean ASES score augmented significant from 20.5 to 78.7 (p < 0.001). The 2
year TE’s ranged from 1 to 0.09. We had no patient with a negative TE. A higher Hamada grade was associated with
better TE’s (Hamada grade 4+ vs. 2, p-value 0.042). For age and dominant side there were weak associations where
those aged 80+ and dominant side had better TE’s. The patients with higher ASA grade had lower TE’s (ASA grade 4+
vs. 1, p-value 0.013). The mean TE’s were 0.77 at 6-months, 0.81 at 1 year, 0.76 at 2 years and 0.73 at 5 years.
Conclusions: The outcome for reverse shoulder arthroplasty can be measured with the treatment effect method; the
2 years TE’s vary from 1 to 0.09. The mean treatment effects change little in the first five postoperative years (from 0.73
to 0.81). The confounders for better TE’s were: higher severity of cuff arthropathy (Hamada grade 3, 4 and 5), less co-
morbidities (ASA Grade 1), higher age (80+) and dominant side. Gender did not influence the 2-year TE’s.
Trial registration: Comité intercantonal d’éthique (Jura, Fribourg, Neuchâtel), number 01/2008, 24.09.2008.
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Background
Although shoulder arthroplasty is less common than
knee or hip arthroplasty (in 2015 there were 83,886
primary hip arthroplasties, 94,023 primary knee arthro-
plasties, compared to 5221 primary shoulder arthroplas-
ties in the UK NJR) [1] the outcome seems to be just as
successful or even better in reducing pain and ameliorat-
ing shoulder function [2–7] compared to other total
joint arthroplasties. From 1991 to 2010 the number of
shoulder arthroplasties increased very rapidly with 98%
for shoulder hemiarthroplasty and 393% especially for
reverse total shoulder arthroplasty (RSA) in the New
York State [8]. In California, a similar trend was found
with the incidence for shoulder arthroplasties rising from
6.1/100′000 insured persons to 13.4/100′000 persons in a
large cohort of an integrated healthcare system [9].
Reverse total shoulder arthroplasty (RSA) is a bio-
mechanical unique concept of replacement surgery in
the shoulder successfully used in elderly patients with
cuff tear arthropathy [10]. The underlying concept was
to reverse the “ball and socket” principle of the shoulder
joint to lengthen the lever arm for the deltoid muscle
and the rotator cuff [10] and was first described 1994 by
Grammont [11]. The type of prosthesis used in this
study (Affinis® inverse, Fa Mathys, Bettlach, Switzerland)
was developed and introduced to the market in 2007. It
has been clinically and radiographically tested [12] and
can be followed in the implant registries of the
Netherlands, UK, AUS and NZ. The outcomes of RSA is
promising and the good mid-term results are docu-
mented in different studies [6, 7, 13–16]. The long-term
outcomes (> 10 years) showed a deterioration of clinical
results compared to mid-term results and a prosthesis
survivorship of 93% [17].
The treatment effect (TE) is a simple method to calcu-
late the outcome for every patient individually; TE =
score reduction/baseline score (see Fig. 1). The TE mea-
sures the amount of amelioration for a treatment. A
positive TE corresponds to an amelioration, a TE = 0 to
an unchanged situation and a negative TE to a worsen-
ing. The highest TE is 1 and corresponds to a patient
without complaints after intervention [18, 19]. This kind
of outcome analysis is not possible with “classical out-
come” which compares the mean scores before and after
treatment for a cohort. The TE method describes the
variable outcome of each patient, enables closer analysis
of outcome and of confounders. The method has been
applied to measure outcomes of total hip/knee arthro-
plasty, but not yet to shoulder arthroplasty [18].
The primary aim of this study was to measure the TE’s
for RSA 6, 12, 24 and 60 months postoperatively. The
secondary aim was to analyze the influence of con-
founders (Hamada grade of cuff arthropathy, age, gen-
der, dominant side, ASA grade) on the outcome.
Methods
The European shoulder study group consists of five
clinics specialized in shoulder surgery in three different
countries (three clinics in Germany, two in France and
one in Switzerland). Each clinic included their first con-
secutive patients in this open multicenter study. In-
cluded were patients with unilateral cuff arthropathy
Hamada grade > =2 [20] who agreed to the informed
consent approved by the local ethical committee. Ex-
cluded were the patients with trauma/fracture, second-
ary osteoarthritis, no informed consent, with rheumatoid
arthritis, neoplasia, with incomplete data and who had a
revision (change of basic parts of the implants) in the
first 2 years.
Each patient had a primary assessment before surgery
with PROM’s (patient reported outcome measurements)
in paper form and a clinical/functional examination to
calculate the ASES score (American shoulder and elbow
surgeons score [20]) and Constant score respectively
[21]. In addition, the following information were
collected: sociodemographic information (gender, age),
Fig. 1 Calculating treatment effects: 3 examples
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dominance, side of the affected shoulder, and American
Society of Anesthesiologists (ASA) grades as score for
general comorbidities. The ASA definitions were: ASA 1
normal healthy person, ASA 2 patient with mild systemic
disease, ASA 3 patient with severe systemic diseases, and
ASA 4 patient with severe systemic diseases that is a con-
stant threat to life [22]. Every patient had preoperative
radiological assessment with standardized x-rays (shoulder
ap/scapula tangential) and MRI or CT-Scan to evaluate
the Hamada grade of cuff arthropathy [20].
Each patient had reversed total shoulder arthroplasty
(Affinis® inverse, Fa Mathys, Bettlach, Switzerland) in a
standardized way in beach chair position with cement-
less fixation of the base plate of the glenoid component
and non-cemented or cemented fixation of the stem.
The postoperative treatment with immobilization, phys-
ical therapy and beginning of loadbearing of the arm
was individual and defined by each participating clinic.
Each patient had at least one complete follow up
within 2 years with identical PROM’s to calculate ASES
score and a clinical examination for the Constant Score.
If possible the identical PROM’s were also collected 5
years after surgery. All data were documented separately
in a central register. The ASES Score was used for the
outcome as described in the original publication (50%
pain, 50% activities of daily living (ADL)), but for correct
calculation of the treatment effect the ASES score was
normalized to a score from 0 (best) to 100 (worst). The
ASES has just two domains of pain and ADL, and hence
was preferred to the Constant Score for the analysis, as
this has too many dimensions (symptoms, ROM, force,
ability to work).
Statistical methods
The outcome is measured as treatment effects (TE = (pre-
operative score – postoperative score) / preoperative
score). The calculations were performed for each patient
at each follow up (6, 12, 24 and 60months). The ASES
Score had to be inversed (0 = best, 100 = worse) to allow
us to calculate correctly the TE’s. The confounders of
interest were: Hamada grade of cuff arthropathy, age, gen-
der, dominance, side of the affected shoulder, general co-
morbidities measured using ASA grades.
Descriptive statistics (mean, standard deviation for
continuous variables and number, percentage for cat-
egorical) are used to exclude a selection bias by the pa-
tients that had a baseline assessment and no follow up.
Fig. 2 Flow chart of the patients
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Box-whisker plots describe change in ASES and Con-
stant scores over pre-operative and follow up time
points. Kernel density plots describe the distribution of
TE’s over different follow ups. Linear regression model-
ing was used to describe the association of the con-
founders of interest.
Results
The study included 203 patients. Twenty had to be ex-
cluded (six for death not related to treatment, four for sur-
gical revision of large parts with a good result in the
further follow ups, and ten who were lost to follow up
with a baseline assessment) (Fig. 2). This gave 183 patients
with at least one clinical follow up in the first 5 years post-
operatively, of whom 168 had a complete 2-year follow
up ASES score (173 for the Constant Score) and 118
a complete 5-year follow up ASES score. The baseline
pain, ASES and Constant scores of all included and
excluded patients did not differ significantly (Table 1).
By 2 years, the mean ASES score augmented from 20.5 to
78.7 (a difference of 58.2 95% CI (55.3 to 61.1), p < 0.001)
(Fig. 3a), and the Constant score from 25.4 to 67.8 (a differ-
ence of 42.4 95% CI (39.9 to 44.9), p < 0.001) (Fig. 3b).
The TE’s ranged from the maximum 1 to 0.09 for the
2-years follow up. We had no patient with a negative
score. The median 2-years TE was 0.76 95%CI (0.73,
0.79) (see Fig. 4). Comparing different follow-up inter-
vals we found only small differences between the distri-
butions of the mean TE’s at 6 months, 1, 2 and 5-years
(See Fig. 5), being 0.77, 0.81, 0.76 and 0.73 respectively.
There was some evidence of an association of Hamada
grade on 2-year outcomes. The patients with a cuff tear
arthropathy Hamada grade 4 and 5 had a mean TE that
was 0.8 points higher compared to grade 2 as reference
(p = 0.042) (Table 2).
The TE’s differed weakly according to confounding
factors of age, and dominant side but not for gender
(Fig. 6). There was some difference by ASA grade
whereby those with higher ASA grade had reduced TE’s
(median TE in ASA 1 was 0.85 versus 0.67 in ASA
grade 4). This was confirmed by the adjusted linear
regression analysis (ASA grade 4+ vs. 1 difference in
Table 1 Baseline characteristics of the patients at baseline and with at least one clinical follow up over 2 years
All Patients with pre-op data Patients with follow up data
N = 203 N = 183
Hamada Grade
Stage 2 55 (27.1%) 49 (26.8%)
Stage 3 43 (21.2%) 41 (22.4%)
Stage 4a; Stage 4b; Stage 5 105 (51.7%) 93 (50.8%)
Age
Mean (SD) 74.9 (6.7) 74.7 (6.5)
Range 41.9 to 91.6 41.9 to 87.5
Gender
Female 134 (66.0%) 122 (66.7%)
Male 69 (34.0%) 61 (33.3%)
Dominance
Dominant 185 (91.1%) 166 (90.7%)
Non dominant 18 (8.9%) 17 (9.3%)
ASA grade
1 15 (7.4%) 13 (7.1%)
2 22 (10.8%) 20 (10.9%)
3 69 (34.0%) 66 (36.1%)
4 and 5 97 (47.8%) 84 (45.9%)
ASES
Mean (SD) 20.3 (12.9) 20.8 (12.8)
Range 0.0 to 63.3 0.0 to 63.3
Constant
Mean (SD) 24.6 (13.2) 25.3 (13.2)
Range 3.0 to 67.0 3.0 to 67.0
Huber et al. BMC Musculoskeletal Disorders          (2020) 21:397 Page 4 of 8
mean TE’s − 0.16 95% confidence interval (CI) (− 0.03
to − 0.28), p-value 0.013). These findings agree with
the few existing literature for total hip arthroplasty
where a higher ASA grade correlates with lower TE’s
and age, gender have no influence [23].
Discussion
In this study the TE’s of reverse shoulder arthroplasty
were calculated for the first time using a standard score
(ASES). The high treatment effects found correspond to
the clinical success of RSA in patients with cuff arthrop-
athy; mostly all patients had pain reduction and better
function after surgery. The good results of earlier studies
using the t-test were similar in this study (ASES Score
from 20.5 to 78.7, p < 0.001).
The distribution of TE’s as kernel density plots dem-
onstrate that the ameliorations can be seen already 6
months after RSA and change little in the further
follow-up to 5 years (range 0.73 to 0.81 in median TE’s).
The most important factors influencing the outcome
of the examined parameters were: the severity of cuff ar-
thropathy as measured by Hamada grade, the grade of
general comorbidities measured in ASA grades, age, and
dominant side [22]. Interestingly there was no influence
of gender.
This study is valuable because it’s a multicenter study
with a defined pathology and a single treatment; most
other studies have mixed indications (e.g. fracture, revi-
sion) [10, 17]. There are few multicenter studies about
this type of arthroplasty with such a long follow up. Fur-
ther, the data were collected in a standardized way.
Fig. 4 Distribution of the treatment effects (TE’s) for the two-year follow up
a b
Fig. 3 Boxplot diagrams showing change of median score for ASES score, and Constant score pre-operatively and over two-year follow up
Huber et al. BMC Musculoskeletal Disorders          (2020) 21:397 Page 5 of 8
Table 2 Results of linear regression model describing association of Hamada grade on TE’s
Univariable Multivariable
TE’s over 24-months TE’s over 24-months
N = 168 N = 168
Coef (95% CI) P-value Coef (95% CI) P-value
Main Predictor
Hamada Grade
Stage 2 REF REF
Stage 3 0.06 (−0.03, 0.14) 0.194 0.05 (−0.03, 0.14) 0.229
Stage 4a; Stage 4b; Stage 5 0.07 (− 0.01, 0.14) 0.07 0.08 (0.00, 0.15) 0.042
Confounders
Age
< 70 REF REF
70 to 80 0.01 (−0.07, 0.08) 0.894 0.02 (−0.05, 0.10) 0.546
80+ 0.07 (−0.03, 0.17) 0.177 0.09 (−0.01, 0.20) 0.087
Gender
Female REF REF
Male −0.02 (−0.08, 0.05) 0.604 −0.02 (− 0.09, 0.04) 0.518
Dominant side
Dominant REF REF
Non-dominant −0.07 (−0.17, 0.04) 0.213 −0.10 (− 0.21, 0.01) 0.07
ASA grade
1 REF REF
2 −0.03 (−0.17, 0.11) 0.673 −0.02 (− 0.16, 0.12) 0.79
3 −0.07 (− 0.19, 0.06) 0.28 − 0.09 (− 0.21, 0.03) 0.157
4 and 5 − 0.11 (− 0.24, 0.01) 0.065 −0.16 (− 0.28, − 0.03) 0.013
Fig. 5 Kernel density plots of distribution of TE’s for 6, 12, 24 and 60 months follow up
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The limitations of this study were: 1 the results cannot
be directly compared to other shoulder studies because
in this study the TE method was applied the first time to
measure outcome of RSA. 2 The open design of the
study with at least one follow up lead to a slightly re-
duced number of patients with a 2 years follow up. 3 A
bias factor would be the interest and expertise of each
participant surgeon in shoulder surgery and in careful
patient selection to get good results. That might be a
reason to explain that there was no patient with a nega-
tive TE. Existing studies also have more homogeneous
populations, being single center studies, with only a sin-
gle follow up time point that is not consistent between
patients.
Conclusion
The outcome for RSA in patients with cuff arthropathy
can be measured with TE’s using the inverted ASES
score. The excellent results also in this study may ex-
plain the fast success and rapidly increasing numbers of
this treatment. The results can be seen already early 6
months after RSA with only small changes over a longer
follow interval up to 5 years.
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